Edition:
India

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

5.15USD
22 Jan 2018
Change (% chg)

$-0.05 (-0.96%)
Prev Close
$5.20
Open
$5.20
Day's High
$5.30
Day's Low
$5.00
Volume
44,377
Avg. Vol
84,305
52-wk High
$8.25
52-wk Low
$2.35

Chart for

About

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $493.14
Shares Outstanding(Mil.): 55.03
Dividend: --
Yield (%): --

Financials

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

17 Nov 2017

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

14 Nov 2017

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

03 Nov 2017

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

18 Oct 2017

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

02 Oct 2017

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

25 Sep 2017

BRIEF-Arbutus Biopharma Q2 loss per share $0.33

* Arbutus announces corporate update and second quarter 2017 financial results

04 Aug 2017

BRIEF-Arbutus expects to take two experimental hep B drugs into human studies by mid-2018 - CEO

* Arbutus Biopharma expects to take two of its preclinical hep B drugs-in-development into human studies by mid-2018 - ceo Further company coverage:

27 Jul 2017

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

27 Jul 2017

Earnings vs. Estimates